25 August 2020
Visiongain has launched a new pharma report Antibacterial Drugs Market : Forecasts Report of 2020-2030 by Type (Cephalosporins (Rocephin, Sulperazon, Ceftin/Zinnat, Meiact, Flomox, Teflaro, Zeftera, Ceftolozane-tazobactam, Ceftazidime-Avibactam, Others), Penicillins (Generic amoxicillin, Augmentin, Zosyn/Tazocin, Unasyn, Generic Amoxicllin-clavulanic Acid, Amoxil, Others), Fluoroquinolones (Avelox, Cravit, Vigamox, Ciprodex, Cipro/Cirpobay, Geninax, Baxdela, Others), Macrolides (Biaxin/Clarith, Zithromax, Dalacin, Dificid, Solithromycin, Others), by Carbapenems (Invanz, Merrem/Meropen, Primaxin, Doribax, Others), Others (Zyvox, Cubicin, Tygacil, TOBI/TIP, Solodyn, Vibativ, Sirturo, Tedizolid, Oritavancin, Dalbavancin, Nemonoxacin, Surotomycin)), by Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, E-Commerce), by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) and Analysis of Leading Drug Discovery Outsourcing Companies. PLUS, COVID-19 Recovery Scenarios.
This report evaluates the antibacterial drugs market for the period, 2020-2030. The global market is estimated to be worth US$xx million in 2020 and is projected to reach US$xx million in 2030 while growing at a CAGR of xx% over the forecast period from 2020 to 2030.
"The growth of the antibacterial drug market has been relatively stagnant due to generic erosion, lack of new antibacterial drugs entering the market and rising prevalence of treatment-resistant bacteria. Initiatives to regulate the consumption of antibacterial drugs in several national markets, though necessary, have also hampered the growth of this market."
Industry Analyst, Visiongain
Antibacterial drugs form one of the oldest segments of the pharmaceutical industry. More than a hundred new drugs have been launched in this market since the 1940s. However, the strong position of antibiotics is threatened. High use of generic drugs, coupled with a limited pipeline of new therapies, has affected, and will continue to threaten, growth of the antibacterial drugs market. Increasing resistance to current antibiotics is also limiting the treatment choice for healthcare providers.
Although the limited R&D pipeline for new antibacterial drugs, patent expiries and geneticization, will continue to affect the market in the early years of the forecast period 2020 to 2030, opportunities exist. Around seven novel antibacterial drugs will be launched in the next two years, including treatments targeting multidrug-resistant Gram-negative bacterial infections, where high unmet clinical needs exist worldwide.
There are pipeline candidates in this sector that have novel mechanisms of action or improve on existing classes. We discuss the merits of cephalosporin-β-lactases inhibitor combinations, and entirely novel therapeutic monoclonal antibodies targeting S. aureus and P. aeruginosa. This report identifies how industry and market trends affect the drug developers with novel antibiotic therapies, as well as generics manufacturers, and other participants in that industry and market.
Some of the major companies operating in the global antibacterial drugs market are Pfizer Inc., Novartis AG, Merck & Co. Inc., GlaxoSmithKline PLC, BioVersys AG, Allecra Therapeutics GmbH, Adenium Biotech ApS, Bayer AG, Eli Lilly and Company, Johnson & Johnson Services, Inc., AstraZeneca PLC, Allergan, Melinta Therapeutics, SHIONOGI Co., Ltd., and DAIICHI SANKYO COMPANY, LIMITED among other prominent players.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
29 July 2021
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.